Lupin Ltd reported that owing to the encouraging trend seen in the sales of its Suprax brand in the US market, Lupin Pharmaceutical Inc (LPI); a wholly owned subsidiary of the Company, is reorganizing its sales structure, according to the company release.
The sales force currently contracted through Ventiv Health US Sales LLC will be internalized at the beginning of the next quarter. As a part of this reorganization process, LPI will further focus on the high potential Suprax prescribers in the non-paediatric segment as well. Accordingly, LPI has decided to discontinue its co-promotion agreement with Cornerstone BioPharma Inc, the release stated.